These included the possibility that 1 tamoxifen efficacy is associated with CYP2D6 genotype in any of the settings in which the drug is used; 2 that CYP2D6 genotype might be used to identify patients who would benefit most from tamoxifen treatment; 3 that tamoxifen toxicity is similarly associated with CYP2D6 genotype; 4 that drugs which inhibit CYP2D6, such as the selective serotonin reuptake inhibitor antidepressants, commonly taken by patients with breast cancer to treat depression or hot flashes, might reduce tamoxifen efficacy; and 5 that these pharmacogenetic concerns might be avoided entirely by developing endoxifen itself, as a so called improved chemical entitity, to replace tamoxifen as an endocrine therapy for breast cancer patients <a href=https://enhanceyourlife.mom/>priligy dapoxetine buy</a>
